On July 30, 2021 Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, reported that it will host a conference call and webcast on Friday, August 6, 2021 at 8:00 a.m. ET to report financial results for the second quarter ended June 30, 2021 and provide business updates (Press release, Mersana Therapeutics, JUL 30, 2021, https://ir.mersana.com/news-releases/news-release-details/mersana-therapeutics-host-conference-call-announcing-second-2 [SID1234585472]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 3876353. A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com.

On July 30, 2021 NEC reported that (Press release, NEC, JUL 30, 2021, View Source [SID1234585489])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

1. Consolidated Financial Results for the Three-month Period Ended June 30, 2021 (April 1, 2021 – June 30, 2021)

(2) Consolidated Financial Position

2. Dividends

3. Consolidated Financial Results Forecast for the Year Ending March 31, 2022 (April 1, 2021 – March 31, 2022)

*This consolidated financial results falls outside the scope of quarterly review procedures to be performed by certified public accountants or an audit firm. *Explanation concerning the appropriate use of the financial results forecast and other special matters (Adjusted profit (loss)) "Adjusted operating profit (loss)" is an indicator for measuring underlying profitability in order to clarify the contribution of acquired companies to the NEC Group’s overall earnings. It is measured by deducting amortization of intangible assets recognized as a result of M&A and expenses for acquisition of companies (financial advisory fees and other fees) from operating profit (loss). Also, "Adjusted net profit (loss) attributable to owners of the parent" is an indicator for measuring underlying profitability attributable to owners of the parent. It is measured by deducting adjustment items of operating profit (loss) and corresponding amounts of tax and non-controlling interests from net profit (loss) attributable to owners of the parent.

1. Condensed Interim Consolidated Financial Statements and Notes to Condensed Interim Consolidated Financial Statements

On July 30, 2021 Prescient Therapeutics (PTX) reported that it has summarised its operations and cashflow for the June quarter (Press release, Prescient Therapeutics, JUL 30, 2021, View Source;utm_medium=rss&utm_campaign=prescient-therapeutics-asxptx-advances-clinical-studies-in-june-quarter [SID1234585506]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The clinical-stage oncology company focussed on driving multiple cancer programs for its PTX-100 and PTX-200 targeted therapies.

In April, the company successfully completed the second cohort for its phase 1b clinical study of PTX-100 and cytarabine in patients with acute myeloid leukemia (AML).

This cohort was dosed with 35 milligrams per square metre (mg/m2) and didn’t observe any safety or toxicity issues. This study is now progressing its higher dose level of 45 mg/m2.

Following the quarter, Prescient completed recruitment of patients for a higher dose level in its phase 1b basket study of PTX-100 in a mix of solid and haematological cancers.

A key milestone during the June quarter was Prescient entering a research partnering with the Peter MacCallum Cancer Centre to advance the development of its CAR-T therapy using the OmniCAR platform. Prescient will own any resulting intellectual property from this partnership.

In addition, a cell therapy enhancement program at Carina Biotech has been consolidated and is now being undertaken at Peter Mac which the company believes reflects its growing relationship with the world-renowned researcher.

Prescient spent $1.14 million on operating activities which mainly went towards admin and corporate costs, followed by research and development.

The healthcare stock ended the quarter with $16.09 million in cash.

Company shares were up 5.56 per cent and were trading at 19 cents at 11:48 am AEST.

On June 30, 2021 Polymed Biopharmaceuticals reported an RMB 50 million pre-A round fundraising invested solely by Matrix Partners China (Press release, Polymed Biopharmaceuticals, JUL 30, 2021, View Source [SID1234630621]). The fund raised from this round will be used for strengthening Polymed’s PROTAC Platform, based on which therapeutic projects are carried out targeting several previously undruggable targets, and for supporting the IND filing activities for PB001/ABR085 which is a novel protein tyrosine kinase inhibitor against EGFR exon 20 insertion mutants.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to gain the support from Matrix Partners China", Dr. Jason Shaoyun Xiang, the founder and CEO of Polymed said. He further said "We will move our pipelines full speed ahead in order to create novel efficacious therapies for patients".

Dr Zhiyun Yu, the managing partner for Matrix Partners said: "Polymed has a strong pipeline from their PROTAC technologies and leading kinase inhibitors with the potential to become FIC or BIC. We are particularly appreciating the potential for further clinical development of these projects.

On July 30, 2021 Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), reported that Craig Granowitz, M.D., Ph.D. will join the company as senior vice president and chief medical officer, effective August 2, 2021 (Press release, Lexicon Pharmaceuticals, JUL 30, 2021, View Source [SID1234585454]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Granowitz joins Lexicon with deep and successful leadership experience in the pharmaceutical industry, having previously built global medical organizations at three separate companies. Before joining Lexicon, Dr. Granowitz served as chief medical officer at Amarin Corporation plc, where he was a key leader on the company’s clinical development programs and held a number of other medical, safety and communications responsibilities. Prior to joining Amarin, Dr. Granowitz was senior vice president and head of global medical affairs, global human health at Merck & Co., Inc., where he developed and implemented an entirely new global medical affairs organization following Merck’s merger with Schering-Plough Corporation. Prior to the merger, he held a variety of medical and commercial management positions with Schering-Plough, including group vice president, head of global medical affairs.

"We are very pleased to have Dr. Granowitz join Lexicon as our chief medical officer," said Lonnel Coats, Lexicon’s president and chief executive officer. "He will be instrumental in building out our medical affairs organization and overseeing development of our pipeline. His experience as a physician, scientist and medical affairs leader with notable success in cardiovascular medicine makes him a particularly valuable addition to our management team as we prepare to file a new drug application for sotagliflozin as a therapy for people suffering from heart failure and living with type 2 diabetes."

"I am very excited to join the Lexicon team as we continue to advance sotagliflozin toward filing for regulatory approval," said Craig Granowitz, M.D., Ph.D. "The SOLOIST and SCORED studies clearly demonstrate the potential for sotagliflozin to improve the care of people living with type 2 diabetes and heart failure, particularly those with normal, or "preserved," left ventricular ejection fraction (≥ 50%). I look forward to the opportunity to build on the evolving science around sotagliflozin’s unique mechanism of action and the compelling scientific platform that forms the foundation for Lexicon’s drug discovery and development pipeline"

Dr. Granowitz earned his M.D. from the College of Physicians and Surgeons at Columbia University and his Ph.D. from the Graduate School of Arts and Sciences at Columbia University. He is a recognized expert in cardiovascular health and author of more than 30 peer-reviewed abstracts and manuscripts in respected journals and publications, including: The Journal of the American College of Cardiology, American Association of Clinical Endocrinologist, Academy of Managed Care Pharmacy, American Diabetes Association, American Heart Association, American Society for Preventative Cardiology, European Society of Cardiology, International Society for Pharmacoeconomics and Outcomes Research, National Kidney Foundation, the National Lipid Association and the New England Journal of Medicine.